Subtype
Prostate Carcinoma
CI-CAN-00006533Explore in graph →
429 active trials16 approved drugs20 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006533Explore in graph →
Clinical trials
1,176 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (184)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03741712 | A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC | terminated | Phase 1 / Phase 2 | 9 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03514836 | A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 5 | SOTIO a.s.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02844582 | Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 2 | 2 | University of California, DavisOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT04585932 | Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT01882985 | Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients | completed | Phase 2 | 14 | University of California, IrvineOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT02031328 | Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer(2STAR) | unknown | Phase 1 / Phase 2 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT01576172 | Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 159 | National Cancer Institute (NCI)NIH | 1 | Nov 12, 2020 | clinicaltrials |
| NCT01498978 | Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 10 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT03515577 | Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery(PSMA vs AXUMIN) | completed | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT04586543 | Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma | unknown | Phase 2 | 110 | László MangelOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT03570476 | Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer | terminated | Phase 2 | 2 | University of WashingtonOTHER | 1 | Sep 21, 2020 | clinicaltrials |
| NCT01637402 | A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer | completed | Phase 2 | 41 | Terence Friedlander, MDOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT02125357 | Sequencing Abiraterone and Enzalutamide in mCRPC | completed | Phase 2 | 202 | British Columbia Cancer AgencyOTHER | 1 | Aug 7, 2020 | clinicaltrials |
| NCT01859689 | Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | Jul 27, 2020 | clinicaltrials |
| NCT04486937 | SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation(mCRPC) | unknown | Phase 1 / Phase 2 | 90 | Jiangxi Qingfeng Pharmaceutical Co. Ltd.INDUSTRY | 0 | Jul 27, 2020 | clinicaltrials |
| NCT02168062 | Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer | terminated | Phase 2 | 57 | University of California, San FranciscoOTHER | 1 | Jul 23, 2020 | clinicaltrials |
| NCT03506997 | Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer(PERSEUS1) | unknown | Phase 2 | 100 | Institute of Cancer Research, United KingdomOTHER | 1 | Jul 22, 2020 | clinicaltrials |
| NCT03827473 | Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer(ACADEMIC) | terminated | Phase 2 | 1 | University of UtahOTHER | 1 | Jun 25, 2020 | clinicaltrials |
| NCT02691975 | A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients | unknown | Phase 1 / Phase 2 | 197 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 13, 2020 | clinicaltrials |
| NCT01787331 | Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer | completed | Phase 2 | 21 | University of California, San FranciscoOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02429193 | Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA(BARRIER-P) | completed | Phase 2 | 16 | University Health Network, TorontoOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT00937768 | Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy | terminated | Phase 2 | 16 | Mayo ClinicOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT00450749 | Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Dec 18, 2019 | clinicaltrials |
| NCT04188587 | 177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer | unknown | Phase 2 | 30 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Dec 6, 2019 | clinicaltrials |
| NCT02091531 | Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients | completed | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT04148885 | A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 44 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Nov 4, 2019 | clinicaltrials |
| NCT01253642 | Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel | terminated | Phase 2 | 11 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 2, 2019 | clinicaltrials |
| NCT01126879 | Genistein in Treating Patients With Prostate Cancer | terminated | Phase 2 | 12 | Northwestern UniversityOTHER | 1 | Sep 10, 2019 | clinicaltrials |
| NCT03077659 | Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer | completed | Phase 2 | 16 | NanOlogy, LLCINDUSTRY | 1 | Aug 20, 2019 | clinicaltrials |
| NCT01682772 | TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer(TOPARP) | unknown | Phase 2 | 148 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 15, 2019 | clinicaltrials |
| NCT04031378 | Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer | unknown | Phase 2 | 100 | Fundacao ChampalimaudOTHER | 1 | Jul 24, 2019 | clinicaltrials |
| NCT01881867 | CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 54 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 9, 2019 | clinicaltrials |
| NCT01543776 | Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer | completed | Phase 2 | 72 | University of ChicagoOTHER | 2 | Jul 5, 2019 | clinicaltrials |
| NCT01026623 | Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT01927627 | Enzalutamide in Patients With High-risk Prostate Cancer | completed | Phase 2 | 42 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 20, 2019 | clinicaltrials |
| NCT01487863 | Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer | completed | Phase 2 | 69 | DendreonINDUSTRY | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01530269 | C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma | completed | Phase 2 | 300 | Phoenix Molecular ImagingOTHER | 1 | Mar 7, 2019 | clinicaltrials |
| NCT01163084 | Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer | terminated | Phase 1 / Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2019 | clinicaltrials |
| NCT00570700 | Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer | completed | Phase 2 | 38 | University of California, IrvineOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT01120470 | OGX-427 in Castration Resistant Prostate Cancer Patients | completed | Phase 2 | 74 | British Columbia Cancer AgencyOTHER | 2 | Feb 15, 2019 | clinicaltrials |
| NCT02012920 | A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer | completed | Phase 2 | 200 | Innocrin PharmaceuticalINDUSTRY | 4 | Feb 1, 2019 | clinicaltrials |
| NCT02361086 | A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 21 | Innocrin PharmaceuticalINDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT03147196 | Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 0 | Jan 22, 2019 | clinicaltrials |
| NCT01148069 | Surgery Combined With Intensity Modulated Radiation Therapy - Image-Guided Radiation Therapy (IMRT-IGRT) in Locally-advanced Prostate Cancers(TARGET) | completed | Phase 2 | 63 | Rennes University HospitalOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT02047253 | Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment | completed | Phase 2 | 28 | University of Alabama at BirminghamOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT01832259 | A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection | completed | Phase 2 | 30 | University of UtahOTHER | 1 | Dec 12, 2018 | clinicaltrials |
| NCT01703065 | Cabozantinib in Men With Castration-Resistant Prostate Cancer | terminated | Phase 2 | 9 | University of WashingtonOTHER | 1 | Dec 4, 2018 | clinicaltrials |
| NCT01091103 | Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide | completed | Phase 2 | 60 | PfizerINDUSTRY | 1 | Oct 23, 2018 | clinicaltrials |
| NCT03696186 | Selective Treatment According to Molecular Subtype of Prostate Cancer(STAMP) | unknown | Phase 2 | 300 | Tianjin Medical University Second HospitalOTHER | 1 | Oct 9, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Feb 5, 2021source: clinicaltrials